Top Stories
Radiotherapeutics firm Full-Life Technologies snagged $110 million in a series D round, while Accro Bioscience raised a $50-million series C.
In 20 evaluable patients with vascular anomalies, zovegalisib led to a volumetric response rate of 60%.
Kosmos will be embedded across discovery and development activities as Incyte looks to use experimental, clinical and biomarker data more directly in research decisions.
Results from BE BOLD showed that 49.1% of patients on Bimzelx achieved ACR50 at week 16, versus 38.4% of those treated with AbbVie's Skyrizi.
The company also secured $290 million in a concurrent private placement.
Conference News
The 2026 European Society for Radiotherapy and Oncology (ESTRO 2026) was held in Stockholm, Sweden, from May 15 to 19 local time. At this conference, Henlius' innovative anti-PD-1 monoclonal antibody(...
Late-breaking oral presentation to highlight AlloNK + rituximab clinical responses comparable to autologous CAR T-cell therapy in 31 patients with rheumatologic diseases, including 71% ACR50 response ...
This framework demonstrates how a single, centralised infrastructure can unlock the kind of patient insights that traditional siloed studies struggle to generate in rare diseases.”— Dr Sherif Raouf, C...
ORJ-001 achieved therapeutic exposure and was well tolerated in Phase 1 study, supporting company’s plans to initiate Phase 2 clinical trial in IPF patients Data from preclinical studies of ORJ-001 de...
Randomized, placebo-controlled challenge study demonstrated reduced viral load, reduced inflammation, maintained lung function and improved patient-reported outcomes in COPD patients treated with vape...
